Hangzhou-based oncology-focused clinical stage biotech Bliss Bio has announced that its clinical filing for the Category 1 therapeutic biologic product injectable BB-1709 has been accepted for review by the Center for Drug Evaluation (CDE). This marks a significant milestone in the development of BB-1709, a potential first-in-class antibody drug conjugate (ADC) being developed to treat solid tumors.
BB-1709 Development
BB-1709 obtained clinical approval in the US last month, highlighting its potential as a groundbreaking treatment for solid tumors. Bliss Bio is leveraging its expertise in oncology to advance this ADC through clinical trials, aiming to address significant unmet medical needs in the treatment of various solid tumor types.
Company Profile
Founded in 2017, Bliss Bio is also developing BB-1701 and BB-1705, two additional ADCs targeting HER2 and EGFR respectively. These programs further demonstrate Bliss Bio’s commitment to innovation and its focus on developing novel therapies for cancer patients. The acceptance of the BB-1709 clinical filing by the CDE underscores the company’s progress in advancing its pipeline and expanding its global footprint.-Fineline Info & Tech
